OncoGeneX Technologies Inc.
We can tell you that OncoGeneX Technologies Inc. is a…
If you know more about OncoGeneX Technologies Inc., you can add more facts here »
Similar topics in Freebase
-
Genentech
Genentech Inc. (NYSE: DNA), a composite of Genetic Engineering Technology, Inc., is a leading biotechnology corporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. Considered the founder of the biotechnology industry, Genentech... -
Amgen
Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the largest independent biotech firm. The company employs approximately 14,000 staff members including the 125 Allied-Barton Security... -
Archer Biosciences, Inc.
Archer Biosciences is developing novel therapeutics to treat cancer with a focus on overcoming resistance mechanisms, increasing efficacy, and minimizing side effects. -
Millennium Pharmaceuticals
Millennium Pharmaceuticals, Inc., The Takeda Oncology Company is a biopharmaceutical company based in Cambridge, Massachusetts. The Company markets Velcade (bortezomib) for injection, a cancer product, and has a growing clinical development pipeline of product candidates. Millennium research,... -
UCB
UCB (Union chimique belge; Euronext: UCB), is a biopharmaceutical manufacturer headquartered in Brussels (Belgium). UCB was founded in 1928 by Emmanuel Janssen, a Belgian businessman. Initially focused on industrial chemicals, the company also included a small pharmaceutical division based around... -
Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global American pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson is known for its... -
Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company’s research platforms are anchored by two major programs that center on oligonucleotides (RNA- and DNA-... -
BiPar Sciences Inc.
BiPar Sciences is developing tumor selective therapeutics for oncology. BiPar Sciences's lead candidate is a PARP inhibitor in clinical II trials for breast cancer, ovarian cancer, and solid tumors. -
Cell Therapeutics, Inc.
-
Biosyntech Inc
